PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23524664-1 2013 OBJECTIVE: The aim of this study was to assess the potential impact of the pharmacogenetic variability of CYP2B6 and ABCB1 genes on the pharmacokinetics of mitotane. Mitotane 156-164 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 25096913-0 2014 Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. Mitotane 0-8 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 25096913-2 2014 It was previously demonstrated that mitotane potentiates chemotherapeutic drugs cytotoxicity in cancer cells displaying chemoresistance due to P-glycoprotein (P-gp), an efflux pump involved in cancer multidrug resistance. Mitotane 36-44 ATP binding cassette subfamily B member 1 Homo sapiens 143-157 25096913-2 2014 It was previously demonstrated that mitotane potentiates chemotherapeutic drugs cytotoxicity in cancer cells displaying chemoresistance due to P-glycoprotein (P-gp), an efflux pump involved in cancer multidrug resistance. Mitotane 36-44 ATP binding cassette subfamily B member 1 Homo sapiens 159-163 25096913-8 2014 We found that very low mitotane concentrations sensitize ACC cells to the cytotoxic effects of doxorubicin, depending on P-gp expression. Mitotane 23-31 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 25096913-9 2014 In addition, mitotane directly inhibits P-gp detoxifying function, allowing doxorubicin cytotoxic activity. Mitotane 13-21 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 9815696-5 1997 Mitotane, at a concentration achieved in this patient"s plasma, completely reversed the Pgp-related resistance both in the Pgp-overexpressing KB8-5 cell line and in the patient"s tumor cells. Mitotane 0-8 ATP binding cassette subfamily B member 1 Homo sapiens 88-91 12015757-2 2002 Based on in vitro studies demonstrating the efficacy of mitotane as a P-glycoprotein (Pgp) antagonist, and expression of high levels of Pgp in ACC, the authors conducted a study of infusional doxorubicin, vincristine, and etoposide with oral mitotane +/- surgical resection in patients with metastatic ACC. Mitotane 56-64 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 12015757-2 2002 Based on in vitro studies demonstrating the efficacy of mitotane as a P-glycoprotein (Pgp) antagonist, and expression of high levels of Pgp in ACC, the authors conducted a study of infusional doxorubicin, vincristine, and etoposide with oral mitotane +/- surgical resection in patients with metastatic ACC. Mitotane 56-64 ATP binding cassette subfamily B member 1 Homo sapiens 86-89 12015757-13 2002 Mitotane levels > 10 microg/mL, previously shown to antagonize Pgp in vitro, were achieved in 25 of 36 patients (69%). Mitotane 0-8 ATP binding cassette subfamily B member 1 Homo sapiens 66-69 9815696-5 1997 Mitotane, at a concentration achieved in this patient"s plasma, completely reversed the Pgp-related resistance both in the Pgp-overexpressing KB8-5 cell line and in the patient"s tumor cells. Mitotane 0-8 ATP binding cassette subfamily B member 1 Homo sapiens 123-126 9815696-6 1997 On the basis of these in vitro results, the patient was treated with a combination of multidrug resistance drugs (doxorubicin, vincristine, and etoposide) plus mitotane as a Pgp modulator. Mitotane 160-168 ATP binding cassette subfamily B member 1 Homo sapiens 174-177 7544429-6 1995 The finding that multidrug resistance mediated by MDR-1/P-glycoprotein can be reverted by mitotane provides a rational basis for exploring the use of mitotane in combination with chemotherapeutic agents. Mitotane 90-98 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 7544429-6 1995 The finding that multidrug resistance mediated by MDR-1/P-glycoprotein can be reverted by mitotane provides a rational basis for exploring the use of mitotane in combination with chemotherapeutic agents. Mitotane 90-98 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 7544429-6 1995 The finding that multidrug resistance mediated by MDR-1/P-glycoprotein can be reverted by mitotane provides a rational basis for exploring the use of mitotane in combination with chemotherapeutic agents. Mitotane 150-158 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 7544429-6 1995 The finding that multidrug resistance mediated by MDR-1/P-glycoprotein can be reverted by mitotane provides a rational basis for exploring the use of mitotane in combination with chemotherapeutic agents. Mitotane 150-158 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 8098948-5 1993 On the other hand, 2 patients with P-glycoprotein-negative tumours showed progression of the disease despite mitotane treatment. Mitotane 109-117 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 1675220-0 1991 Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. Mitotane 0-8 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 1675220-0 1991 Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. Mitotane 0-8 ATP binding cassette subfamily B member 1 Homo sapiens 107-121 1675220-4 1991 The present study demonstrates that decreased drug accumulation mediated by mdr-1/Pgp can be overcome by clinically achievable concentrations of mitotane (o,p"-DDD). Mitotane 145-153 ATP binding cassette subfamily B member 1 Homo sapiens 76-81 1675220-4 1991 The present study demonstrates that decreased drug accumulation mediated by mdr-1/Pgp can be overcome by clinically achievable concentrations of mitotane (o,p"-DDD). Mitotane 145-153 ATP binding cassette subfamily B member 1 Homo sapiens 82-85 1675220-4 1991 The present study demonstrates that decreased drug accumulation mediated by mdr-1/Pgp can be overcome by clinically achievable concentrations of mitotane (o,p"-DDD). Mitotane 155-163 ATP binding cassette subfamily B member 1 Homo sapiens 76-81 1675220-4 1991 The present study demonstrates that decreased drug accumulation mediated by mdr-1/Pgp can be overcome by clinically achievable concentrations of mitotane (o,p"-DDD). Mitotane 155-163 ATP binding cassette subfamily B member 1 Homo sapiens 82-85 1675220-8 1991 The finding that multidrug resistance mediated by mdr-1/Pgp can be reversed by mitotane provides a rational basis for exploring the use of mitotane in combination with natural product chemotherapeutic agents in adrenocortical cancer. Mitotane 79-87 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 1675220-8 1991 The finding that multidrug resistance mediated by mdr-1/Pgp can be reversed by mitotane provides a rational basis for exploring the use of mitotane in combination with natural product chemotherapeutic agents in adrenocortical cancer. Mitotane 79-87 ATP binding cassette subfamily B member 1 Homo sapiens 56-59 1675220-8 1991 The finding that multidrug resistance mediated by mdr-1/Pgp can be reversed by mitotane provides a rational basis for exploring the use of mitotane in combination with natural product chemotherapeutic agents in adrenocortical cancer. Mitotane 139-147 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 1675220-8 1991 The finding that multidrug resistance mediated by mdr-1/Pgp can be reversed by mitotane provides a rational basis for exploring the use of mitotane in combination with natural product chemotherapeutic agents in adrenocortical cancer. Mitotane 139-147 ATP binding cassette subfamily B member 1 Homo sapiens 56-59